United States was Mesa Laboratories’s largest region in fiscal 2026, bringing in $116.90M of $249.13M (47%).
| Geography | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | FY 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $117.28M | $106.40M | $116.62M | $116.90M | |||||||
| Other | $76.00M | $84.86M | $99.05M | $111.79M | |||||||
| Non-Us | — | — | — | — | |||||||
| Foreign | — | — | — | — | |||||||
| China | $25.80M | $24.93M | $25.31M | $20.45M | |||||||
| Total | $219.08M | $216.19M | $240.98M | $249.13M |
Mesa Laboratories brought in $249.13M from its three regions in fiscal 2026, the year ended March 31, 2026. That was up 3.4% from $240.98M in fiscal 2025. United States was the largest at $116.90M (46.9%), ahead of Other at $111.79M (44.9%) and China at $20.45M (8.2%).
Compared with fiscal 2025, Other grew fastest, up 12.9% to $111.79M, while China fell the most, down 19.2% to $20.45M. From fiscal 2023 to 2026, combined revenue from these regions grew from $219.08M to $249.13M, a compound annual growth rate of 4.4%. United States' share of the total fell from 53.5% to 46.9%.
Consumables was Mesa Laboratories’s largest product and service line in fiscal 2021, bringing in $45.87M of $89.60M (51%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2021 |
|---|---|---|---|---|
| Product | $72.17M | — | ||
| Consumables | — | $45.87M | ||
| Hardware & Software | — | $29.97M | ||
| Service | $24.01M | $13.76M | ||
| Total | $96.18M | $89.60M |
Mesa Laboratories brought in $89.60M from its three product and service lines in fiscal 2021, the year ended March 31, 2021. Mesa Laboratories regrouped these lines after fiscal 2018, so the total does not compare directly with that year's $96.18M. Consumables was the largest at $45.87M (51.2%), ahead of Hardware & Software at $29.97M (33.4%) and Service at $13.76M (15.4%).
Mesa Laboratories began breaking out Consumables in fiscal 2021 and Hardware & Software in fiscal 2021. Mesa Laboratories stopped reporting Product as a separate line after fiscal 2018, when it brought in $72.17M.
Sterilization & Disinfection Control was Mesa Laboratories’s largest segment in fiscal 2021, bringing in $45.87M of $89.78M (51%).
| Statement Business Segments | FY 2011 | FY 2016 | FY 2018 | FY 2019 | FY 2020 | FY 2021 |
|---|---|---|---|---|---|---|
| Sterilization & Disinfection Control | — | $39.67M | $42.65M | $45.87M | ||
| Instruments | $57.45M | $24.50M | — | — | ||
| Revenue, Net | — | — | — | — | ||
| Calibration Solutions | — | — | $33.52M | $29.97M | ||
| Continuous Monitoring | $18.63M | $18.24M | — | — | ||
| Sterilzation & Disinfection Control | $1.11M | — | — | — | ||
| Biopharmaceutical Development | — | — | $19.87M | $13.94M | ||
| Cold Chain Monitoring | — | $13.81M | — | — | ||
| Cold Chain Packaging | — | — | — | — | ||
| Total | $77.19M | $96.21M | $96.04M | $89.78M |
Mesa Laboratories brought in $89.78M from its three segments in fiscal 2021, the year ended March 31, 2021. That was down 6.5% from $96.04M in fiscal 2020. Sterilization & Disinfection Control was the largest at $45.87M (51.1%), ahead of Calibration Solutions at $29.97M (33.4%) and Biopharmaceutical Development at $13.94M (15.5%).
Compared with fiscal 2020, Sterilization & Disinfection Control grew fastest, up 7.5% to $45.87M, while Biopharmaceutical Development fell the most, down 29.8% to $13.94M.
Mesa Laboratories began breaking out Sterilization & Disinfection Control in fiscal 2019, Calibration Solutions in fiscal 2020 and Biopharmaceutical Development in fiscal 2020. Mesa Laboratories stopped reporting Instruments ($24.50M in fiscal 2019), Continuous Monitoring ($18.24M in fiscal 2019), Cold Chain Monitoring ($13.81M in fiscal 2019) and one other as separate segments.
Mesa Laboratories (MLAB) reports its revenue by geography, by product and service and by statement business segments. In fiscal 2026, United States was its largest region, bringing in $116.90M (46.9% of the total), followed by Other at $111.79M (44.9%).
United States was Mesa Laboratories' largest region in fiscal 2026, bringing in $116.90M, or 46.9% of the $249.13M total across its three regions.
Consumables was Mesa Laboratories' largest product and service line in fiscal 2021, bringing in $45.87M, or 51.2% of the $89.60M total across its three product and service lines.
Sterilization & Disinfection Control was Mesa Laboratories' largest segment in fiscal 2021, bringing in $45.87M, or 51.1% of the $89.78M total across its three segments.
Among Mesa Laboratories' regions that make up at least 2% of revenue, Other grew fastest in fiscal 2026, up 12.9% from $99.05M to $111.79M.
Every figure comes from Mesa Laboratories' annual financial filings, as reported. Each line keeps the name Mesa Laboratories gives it, and years follow its fiscal calendar.
Mesa Laboratories' revenue by geography goes back to fiscal 2016, with figures through fiscal 2026. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.